The challenge of Helicobacter pylori resistance to antibiotics: The comeback of bismuth-based quadruple therapy

Therapeutic Advances in Gastroenterology

Volumn 5, Issue 2, 2012, Pages 103-109

  Mégraud, Francis ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Antimicrobial susceptibility testing; Bismuth salts; BMT (Pylera ); Clarithromycin; Sequential therapy

Indexed keywords

AMOXICILLIN; BISMUTH; BISMUTH CITRATE; CLARITHROMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING); GUANINE QUADRUPLEX; HELIDAC; LEVOFLOXACIN; METRONIDAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL PRACTICE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IN VITRO STUDY; IN VIVO STUDY; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 84857546266     PISSN: 1756283X     EISSN: 17562648     Source Type: Journal    
DOI: 10.1177/1756283X11432492     Document Type: Review

References (37)

1. Bader J.P. (1987) The safety profile of De-Nol. Digestion 37(Suppl 2): 53–59.
2. Bazzoli F. Zagari R.M. Fossi S. Pozzato P. Roda A. Roda E. (1993) Efficacy and tolerability of a short-term low-dose triple therapy for eradication of Helicobacter pylori. Gastroenterology 104: 40A (Abstract).
3. Borody T.J. Andrews P. Fracchia G. Brandl S. Shortis N.P. Bae H. (1995) Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori. Gut 37: 477–481.
4. Borody T.J. Carrick J. Hazell S.L. (1987) Symptoms improve after the eradication of gastric Campylobacter pyloridis. Med J Aust 146: 450–451.
5. Cambau E. Allerheiligen V. Coulon C. Corbel C. Lascols C. Deforges L. et al. (2009) Evaluation of a new test, genotype Helico D.R., for molecular detection of antibiotic resistance in Helicobacter pylori. J Clin Microbiol 47: 3600–3607.
6. Cammarota G. Cianci R. Cannizzaro O. Cuoco L. Pirozzi G. Gasbarrini A. et al. (2000) Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 14: 1339–1343.
7. de Boer W.A. (2001) A novel therapeutic approach for Helicobacter pylori infection: the bismuth-based triple therapy monocapsule. Expert Opin Investig Drugs 10: 1559–1566.
8. de Boer W. Driessen W. Jansz A. Tytgat G. (1995) Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection. Lancet 345: 817–820.
9. de Boer W.A. Driessen W.M. Potters V.P. Tytgat G.N. (1994) Randomized study comparing 1 with 2 weeks of quadruple therapy for eradicating Helicobacter pylori. Am J Gastroenterol 89: 1993–1997.
10. Essa A.S. Kramer J.R. Graham D.Y. Treiber G. (2009) Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing ‘concomitant therapy’ versus triple therapy for Helicobacter pylori eradication. Helicobacter 14: 109–118.
11. European Helicobacter Pylori Study Group. (1997) Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 41: 8–13.
12. Fischbach L. Evans E.L. (2007) Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 26: 343–357.
13. Ford A.C. Malfertheiner P. Giguere M. Santana J. Khan M. Moayyedi P. (2008) Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol 14: 7361–7370.
14. Fuccio L. Minardi M.E. Zagari R.M. Grilli D. Magrini N. Bazzoli F. (2007) Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 147: 553–562.
15. Gisbert J.P. Calvet X. O'Connor A. Megraud F. O'Morain C.A. (2010) Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol 44: 313–325.
16. Hillemand P. Palliere M. Laquais B. Bouvet P. (1977) Bismuth treatment and blood bismuth levels. Sem Hop 53: 1663–1669.
17. Laine L. Hunt R. El-Zimaity H. Nguyen B. Osato M. Spenard J. (2003) Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 98: 562–567.
18. Lamouliatte H. Cayla R. Regland F. (1993) Amoxicillin-clarithromycin-omeprazole: the best therapy for Helicobacter pylori infection. Acta Gastroenterol Belg 56: A139 (Abstract).
19. Lehours P. Siffre E. Megraud F. (2011) DPO multiplex PCR as an alternative to culture and susceptibility testing to detect Helicobacter pylori and its resistance to clarithromycin. BMC Gastroenterol 11: 112.
20. Luther J. Higgins P.D. Schoenfeld P.S. Moayyedi P. Vakil N. Chey W.D. (2010) Empiric quadruple versus triple therapy for primary treatment of Helicobacter pylori infection: systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol 105: 65–73.
21. Malfertheiner P. Bazzoli F. Delchier J.C. Celinski K. Giguere M. Riviere M. et al. (2011) Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 377: 905–913.
22. Marshall B.J. Goodwin C S. Warren J.R. Murray R. Blincow E.D. Blackbourn S.J. et al. (1988) Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 2: 1437–1442.
23. Megraud F. Coenen S. Versporten A. Kist M. Lopez-Brea M. Hirschl A. et al. (2011) Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Submitted.
24. Megraud F. Lamouliatte H. (2003) Review article: the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 17: 1333–1343.
25. Megraud F. Lehours P. (2007) Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 20: 280–322.
26. Moayyedi P. Mégraud F. Cohard-Radice M. Rivière M. (2011) Quadruple therapy using a 3-in-1 capsule of bismuth subcitrate potassium, metronidazole, and tetracycline (Pylera®) with omeprazole compared with triple therapy for the eradication of Helicobacter pylori: data from a pooled analysis. Submitted.
27. Molina-Infante J. Perez-Gallardo B. Fernandez-Bermejo M. Hernandez-Alonso M. Vinagre G. Duenas C. et al. (2010) Clinical trial: clarithromycin versus levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 31: 1077–1084.
28. NIH (1994) Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in peptic ulcer disease. JAMA 272: 65–69.
29. O'Morain C. Borody T. Farley A. de Boer W.A. Dallaire C. Schuman R. et al. (2003) Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study. Aliment Pharmacol Ther 17: 415–420.
30. Penston J.G. (1994) Review article: Helicobacter pylori eradication – understandable caution but no excuse for inertia. Aliment Pharmacol Ther 8: 369–389.
31. Perna F. Zullo A. Ricci C. Hassan C. Morini S. Vaira D. (2007) Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance. Dig Liver Dis 39: 1001–1005.
32. Romano M. Cuomo A. Gravina A.G. Miranda A. Iovene M.R. Tiso A. et al. (2010) Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut 59: 1465–1470.
33. Russmann H. Adler K. Haas R. Gebert B. Koletzko S. Heesemann J. (2001) Rapid and accurate determination of genotypic clarithromycin resistance in cultured Helicobacter pylori by fluorescent in situ hybridization. J Clin Microbiol 39: 4142–4144.
34. Schabereiter-Gurtner C. Hirschl A.M. Dragosics B. Hufnagl P. Puz S. Kovach Z. et al. (2004) Novel real-time PCR assay for detection of Helicobacter pylori infection and simultaneous clarithromycin susceptibility testing of stool and biopsy specimens. J Clin Microbiol 42: 4512–4518.
35. Treiber G. Ammon S. Schneider E. Klotz U. (1998) Amoxicillin/metronidazole/omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication. Helicobacter 3: 54–58.
36. Tytgat G.N.J. Axon A.T.R. Dixon M.F. Graham D.Y. Lee A. Marshall B.J. (1990) Helicobacter pylori: Causal Agent in Peptic Ulcer Disease? Oxford: Blackwell Scientific Publications.
37. Zullo A. Rinaldi V. Winn S. Meddi P. Lionetti R. Hassan C. et al. (2000) A new highly effective short-term therapy schedule for Helicobacter pylori eradication. Aliment Pharmacol Ther 14: 715–718.